AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24 th Annual Global Investment Conference, being held in New York.
Remi Barbier, President & CEO, will participate in-person at this corporate event. Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.
Event details follow:
Date: Tuesday, September 13 th
Time: 3:30pm to 4:00 Eastern Time
Webcast: https://journey.ct.events/view/ffcd827b-9de0-4b05-a6fd-5ea79810a3ee
A live webcast will be available on the “Investors” page of Cassava Sciences’ website, www.CassavaSciences.com . An archived replay will be available for 90 days following the event.
About Cassava Sciences, Inc.
Cassava Sciences Inc. is a clinical stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer's disease. Our novel science is based on stabilizing – but not removing – a critical protein in the brain. We are currently testing simufilam, our lead drug candidate for the proposed treatment of Alzheimer's disease dementia, in a large Phase 3 clinical program under Special Protocol Assessments from the FDA.
Eric Schoen512-296-6757eschoen@cassavasciences.com